Moxetumomab Pasudotox

DRUG5 trials

Conditions

Acute Lymphoblastic Leukemia (ALL)B-Cell Pediatric ALLLeukemiaLeukemia, Hairy CellRelapsed/Refractory Hairy Cell Leukemia

Phase 1

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

TerminatedNCT01891981

M.D. Anderson Cancer CenterLeukemia

Start: 2013-12-17End: 2017-04-12Updated: 2023-10-13

Phase 2

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

TerminatedNCT02227108

MedImmune LLCB-Cell Pediatric ALL

Start: 2014-08-31End: 2015-11-30Updated: 2017-04-06

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

TerminatedNCT02338050

Center for International Blood and Marrow Transplant ResearchAcute Lymphoblastic Leukemia (ALL)

Start: 2015-05-31Updated: 2015-09-16

Phase 3

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

CompletedNCT01829711

MedImmune LLCLeukemia, Hairy Cell

Start: 2013-04-29End: 2019-04-29Updated: 2020-04-08

Unknown Phase

An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

NCT03501615

AstraZenecaRelapsed/Refractory Hairy Cell Leukemia

Updated: 2020-06-29

Journal of Hematology & Oncology2021-02-2484 citations

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Blood2019-11-139 citations

Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.

2019-08-017 citations

Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.

Journal of Clinical Oncology2019-05-20

Treatment of R/R Hairy Cell Leukemia With CD22-Targeting Immunotoxin

Oncology Times2019-02-09

Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity.

Journal of Clinical Oncology2018-05-202 citations

Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of moxetumomab pasudotox (Moxe), an immunotoxin targeting CD22, in adult patients (Pts) with relapsed or refractory hairy cell leukemia (HCL).

Journal of Clinical Oncology2018-05-202 citations

Design Of a Phase 1/2 Study Of Moxetumomab Pasudotox In Adult Patients With Relapsed and/Or Refractory Acute Lymphoblastic Leukemia (ALL)

Blood2013-11-152 citations